1. subjects showing signs of acute respiratory distress syndrome (ards) or respiratory failure necessitating mechanical ventilation at the time of screening; 2. history of severe chronic respiratory disease and requirement for long-term oxygen therapy; 3. subjects showing signs of clinical jaundice at the time of screening; 4. history of moderate and severe liver disease (child-pugh score \>12); 5. subjects requiring renal replacement therapy (rrt) at the time of screening; 6. history of severe chronic kidney disease or requiring dialysis; 7. any uncontrolled active systemic infection requiring admission to an intensive care unit (icu); note: subjects infected with chronic hepatitis b virus or hepatitis c virus will be eligible for the study if they have no signs of hepatic decompensation. note: subjects infected with hiv-1 will be eligible for the study with undetectable viral load and are on a stable art regimen. investigators are required to review the subjects' medical records to confirm hiv-1 rna suppression within the previous 3 months. note: empirical antibiotic treatment for secondary bacterial infections is allowed during the course of study. 8. patients with malignant tumor, or other serious systemic diseases; 9. patients who are participating in other clinical trials; 10. patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to leronlimab (pro 140) are not eligible; and 11. inability to provide informed consent or to comply with test requirements

1. subjects showing signs of acute respiratory distress syndrome (ards) or respiratory failure necessitating mechanical ventilation at the time of screening; 2. history of severe chronic respiratory disease and requirement for long-term oxygen therapy; 3. subjects showing signs of clinical jaundice at the time of screening; 4. history of moderate and severe liver disease (child-pugh score \>12); 5. subjects requiring renal replacement therapy (rrt) at the time of screening; 6. history of severe chronic kidney disease or requiring dialysis; 7. any uncontrolled active systemic infection requiring admission to an intensive care unit (icu); note: subjects infected with chronic hepatitis b virus or hepatitis c virus will be eligible for the study if they have no signs of hepatic decompensation. note: subjects infected with hiv-1 will be eligible for the study with undetectable viral load and are on a stable art regimen. investigators are required to review the subjects' medical records to confirm hiv-1 rna suppression within the previous 3 months. note: empirical antibiotic treatment for secondary bacterial infections is allowed during the course of study. 8. patients with malignant tumor, or other serious systemic diseases; 9. patients who are participating in other clinical trials; 10. patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to leronlimab (pro 140) are not eligible; and 11. inability to provide informed consent or to comply with test requirements

subjects showing signs of acute respiratory distress syndrome (ards) or respiratory failure necessitating mechanical ventilation at the time of screening; history of severe chronic respiratory disease and requirement for long-term oxygen therapy; subjects showing signs of clinical jaundice at the time of screening; history of moderate and severe liver disease (child-pugh score >12); subjects requiring renal replacement therapy (rrt) at the time of screening; history of severe chronic kidney disease or requiring dialysis; any uncontrolled active systemic infection requiring admission to an intensive care unit (icu); note: subjects infected with chronic hepatitis b virus or hepatitis c virus will be eligible for the study if they have no signs of hepatic decompensation. note: subjects infected with hiv-1 will be eligible for the study with undetectable viral load and are on a stable art regimen. investigators are required to review the subjects' medical records to confirm hiv-1 rna suppression within the previous 3 months. note: empirical antibiotic treatment for secondary bacterial infections is allowed during the course of study. patients with malignant tumor, or other serious systemic diseases; patients who are participating in other clinical trials; patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to leronlimab (pro 140) are not eligible; and inability to provide informed consent or to comply with test requirements

subjects showing signs of acute respiratory distress syndrome (ards) or respiratory failure necessitating mechanical ventilation at the time of screening; history of severe chronic respiratory disease and requirement for long-term oxygen therapy; subjects showing signs of clinical jaundice at the time of screening; history of moderate and severe liver disease (child-pugh score >12); subjects requiring renal replacement therapy (rrt) at the time of screening; history of severe chronic kidney disease or requiring dialysis; any uncontrolled active systemic infection requiring admission to an intensive care unit (icu); note: subjects infected with chronic hepatitis b virus or hepatitis c virus will be eligible for the study if they have no signs of hepatic decompensation. note: subjects infected with hiv-1 will be eligible for the study with undetectable viral load and are on a stable art regimen. investigators are required to review the subjects' medical records to confirm hiv-1 rna suppression within the previous 3 months. note: empirical antibiotic treatment for secondary bacterial infections is allowed during the course of study. patients with malignant tumor, or other serious systemic diseases; patients who are participating in other clinical trials; patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to leronlimab (pro 140) are not eligible; and inability to provide informed consent or to comply with test requirements

1. subjects showing signs of acute respiratory distress syndrome (ards) or respiratory failure necessitating mechanical ventilation at the time of screening; 2. history of severe chronic respiratory disease and requirement for long-term oxygen therapy; 3. subjects showing signs of clinical jaundice at the time of screening; 4. history of moderate and severe liver disease (child-pugh score >12); 5. subjects requiring renal replacement therapy (rrt) at the time of screening; 6. history of severe chronic kidney disease or requiring dialysis; 7. any uncontrolled active systemic infection requiring admission to an intensive care unit (icu); note: subjects infected with chronic hepatitis b virus or hepatitis c virus will be eligible for the study if they have no signs of hepatic decompensation. note: subjects infected with hiv-1 will be eligible for the study with undetectable viral load and are on a stable art regimen. investigators are required to review the subjects' medical records to confirm hiv-1 rna suppression within the previous 3 months. note: empirical antibiotic treatment for secondary bacterial infections is allowed during the course of study. 8. patients with malignant tumor, or other serious systemic diseases; 9. patients who are participating in other clinical trials; 10. patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to leronlimab (pro 140) are not eligible; and 11. inability to provide informed consent or to comply with test requirements

1. subjects showing signs of acute respiratory distress syndrome (ards) or respiratory failure necessitating mechanical ventilation at the time of screening; 2. history of severe chronic respiratory disease and requirement for long-term oxygen therapy; 3. subjects showing signs of clinical jaundice at the time of screening; 4. history of moderate and severe liver disease (child-pugh score >12); 5. subjects requiring renal replacement therapy (rrt) at the time of screening; 6. history of severe chronic kidney disease or requiring dialysis; 7. any uncontrolled active systemic infection requiring admission to an intensive care unit (icu); note: subjects infected with chronic hepatitis b virus or hepatitis c virus will be eligible for the study if they have no signs of hepatic decompensation. note: subjects infected with hiv-1 will be eligible for the study with undetectable viral load and are on a stable art regimen. investigators are required to review the subjects' medical records to confirm hiv-1 rna suppression within the previous 3 months. note: empirical antibiotic treatment for secondary bacterial infections is allowed during the course of study. 8. patients with malignant tumor, or other serious systemic diseases; 9. patients who are participating in other clinical trials; 10. patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to leronlimab (pro 140) are not eligible; and 11. inability to provide informed consent or to comply with test requirements